ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2018

New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…

Filed under:Drug Updates Tagged with:filgotinibhipkneeKnee Osteoarthritis (OA)osteoarthritis (OA)Painpsoriatic arthritistanezumab

Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs

Lisa Rapaport  |  August 13, 2018

(Reuters Health)—Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests. Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesfracture riskFracturesOsteoporosisosteoporosis treatments

Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe

Nate Raymond  |  August 8, 2018

(Reuters)—Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication. The tentative deal announced by the Arizona-based drugmaker marked a major step in Insys’ efforts to resolve an…

Filed under:Uncategorized Tagged with:FentanylInsys settlementInsys Therapeutics IncJohn KapoorMichael BabichSubsys opioid drugU.S. opioid kickback probe

Anxiety, Depression May Help Predict Outcome of Low Back Pain Treatment

Lorraine L. Janeczko  |  July 31, 2018

NEW YORK (New York)—Patients with anxiety and depression may be less satisfied than other patients with their chronic low back pain (CLBP) treatments, new research suggests. “Patients with anxiety/depression symptoms experienced more pain severity and more pain-related functional, social, and emotional disability, and they were less satisfied with care, compared with the other groups,” the…

Filed under:ConditionsPain Syndromes Tagged with:anxiety disordersBack painChronic painDepressionlow back painPain Management

Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals

Manas Mishra  |  July 26, 2018

(Reuters)—An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. Opioid abuse has reached epidemic proportions in the United States and drugmakers have been looking for less addictive…

Filed under:Drug UpdatesOsteoarthritis and Bone Disorders Tagged with:Eli Lilly and Coexperimental osteoarthritis drugOpioid abuseopioid epidemicPfizer Inc.safer alternative to opioidstanezumab

Ethics Forum: What to Do with the Inherited Opioid Patient?

Edward P. Rose, MD  |  July 19, 2018

A 67-year-old man with a recent onset of diffuse muscular pain and stiffness and an erythrocyte sedimentation rate of 55 is referred to you by his family practitioner. He has a history of non-insulin-dependent diabetes mellitus, but no history of headaches or swollen joints. He has chronic back pain, has had two surgeries and was…

Filed under:Ethics Tagged with:opioid crisis

Patient Education Videos Help Them Understand & Manage Their Disease

Kathy Holliman, MEd  |  July 19, 2018

Videos designed to help patients understand and manage chronic rheumatologic diseases can lead to gains in clarity about the disease duration, symptoms, medications, and the importance of regular visits with a physician. A study published in a recent issue of Arthritis Care & Research looks at the development and impact of three educational videos for…

Filed under:Patient Perspective Tagged with:patient communicationpatient educationpatient management

Rheumatologists in U.S. on J-1 Visas Face Challenges After Fellowship

Shing Law, BM, BCh  |  July 19, 2018

I am an alien rheumatologist. Are you? One in five rheumatology fellows is considered an alien. Under the Code of Federal Regulations Title 22 Chapter I Subchapter G Part 62 Subpart B Section 62.27, an alien physician is a foreign national who is a graduate of a school of medicine who comes to the U.S….

Filed under:Professional Topics Tagged with:alien physiciansforeign nationals

Rheumatology Awards & Appointments for June 2018

Ann-Marie Lindstrom  |  June 21, 2018

Lurie Prize Goes to Autoimmune Researcher Zhijian “James” Chen, PhD, is this year’s recipient of the Lurie Prize in Biomedical Sciences for his 2012 discovery of the enzyme cyclic GMP-AMP synthase (cGAS). Dr. Chen received the prize at the Foundation for the National Institutes of Health Award Ceremony in May. His work revealed the paradoxical…

Filed under:Profiles Tagged with:Dr. Jessica FarrellDr. Timothy NiewoldDr. Zhijian James Chen

rzstudio / shutterstock.com

Prescribing Hope: The Placebo Effect Endures

Philip Seo, MD, MHS  |  June 21, 2018

“Wait. I can explain.” One could imagine this phrase coming up under many conditions in daily life. When I first became a physician, however, I would never have expected to use this phrase in my clinic. In medical school, I was taught the importance of dialogue in establishing a relationship with a patient. Statistics indicate…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient managementplacebo

  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences